NCT01967381

Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: University of Kentucky · Academic / Other
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The research proposed in this application will determine the initial efficacy, safety and tolerability of a novel drug combination, oxazepam (Serax®) and naltrexone (Revia®), as a pharmacotherapy for methamphetamine (Desoxyn®) dependence. A rigorous, inpatient human laboratory study will be conducted. The proposed study is innovative and important because it will provide the impetus for the conduct of double blind, placebo-controlled trials to further demonstrate the efficacy of combined oxazepam and naltrexone for managing methamphetamine dependence.

Conditions

• Methamphetamine Abuse
• Methamphetamine Dependence

Interventions

Type	Name	Description
DRUG	Methamphetamine (Desoxyn®)	The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.

Timeline

• Start date: 2013-10-01
• Primary completion: 2018-09-01
• Completion: 2018-09-01
• First posted: 2013-10-22
• Last updated: 2018-09-14

Locations

1 site across 1 country: United States